ASA has been previously shown to inhibit ADP- and thrombin (albeit weakly)- induced VEGF release from platelets [29], [30], while AbciximabTM has been shown to suppress VEGF release from tumor cell aggregated platelets [31]. The gene discussed is VEGFA; the disease is neoplasm.